These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22929325)

  • 1. Pharmacologic vitreolysis: rationale, potential indications, and promising agents.
    Gandorfer A
    Retina; 2012 Sep; 32 Suppl 2():S221-4. PubMed ID: 22929325
    [No Abstract]   [Full Text] [Related]  

  • 2. Conclusion.
    Johnson MW
    Retina; 2012 Sep; 32 Suppl 2():S232. PubMed ID: 22929327
    [No Abstract]   [Full Text] [Related]  

  • 3. Ocriplasmin for pharmacologic vitreolysis.
    Kuppermann BD
    Retina; 2012 Sep; 32 Suppl 2():S225-8; discussion S228-31. PubMed ID: 22929326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic vitreolysis with ocriplasmin: rationale for use and therapeutic potential in vitreo-retinal disorders.
    Khoshnevis M; Sebag J
    BioDrugs; 2015 Apr; 29(2):103-12. PubMed ID: 25812991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic vitreolysis.
    Rhéaume MA; Vavvas D
    Semin Ophthalmol; 2010; 25(5-6):295-302. PubMed ID: 21091015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitreomacular adhesion and neovascular age-related macular degeneration.
    Thompson JT
    Retina; 2012 Sep; 32 Suppl 2():S216-20. PubMed ID: 22929324
    [No Abstract]   [Full Text] [Related]  

  • 7. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic vitreolysis with microplasmin increases vitreous diffusion coefficients.
    Sebag J; Ansari RR; Suh KI
    Graefes Arch Clin Exp Ophthalmol; 2007 Apr; 245(4):576-80. PubMed ID: 16941141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microplasmin for vitreomacular traction.
    Udaondo P; Diaz-Llopis M; Garcia-Delpech S; Salom D; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1859, 1859.e1; author reply 1859-60. PubMed ID: 20816250
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of vitreous in diabetic macular edema.
    Gandorfer A
    Retina; 2012 Sep; 32 Suppl 2():S211-5. PubMed ID: 22929323
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
    Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
    Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.
    Sakuma T; Tanaka M; Mizota A; Inoue J; Pakola S
    Invest Ophthalmol Vis Sci; 2005 Sep; 46(9):3295-9. PubMed ID: 16123432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic vitreodynamics and molecular flux.
    Goldenberg DT; Trese MT
    Dev Ophthalmol; 2009; 44():31-36. PubMed ID: 19494650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deal watch: Alcon invests in first non-surgical therapy for common eye disorder.
    Crunkhorn S
    Nat Rev Drug Discov; 2012 Apr; 11(5):342. PubMed ID: 22543460
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular biology of pharmacologic vitreolysis.
    Sebag J
    Trans Am Ophthalmol Soc; 2005; 103():473-94. PubMed ID: 17057814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microplasmin: ex vivo characterization of its activity in porcine vitreous.
    de Smet MD; Valmaggia C; Zarranz-Ventura J; Willekens B
    Invest Ophthalmol Vis Sci; 2009 Feb; 50(2):814-9. PubMed ID: 18806295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progression of pharmacologic vitreolysis research].
    Zhou H; Ye J
    Zhonghua Yan Ke Za Zhi; 2014 Mar; 50(3):225-9. PubMed ID: 24841819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological vitreolysis].
    Gandorfer A
    Klin Monbl Augenheilkd; 2011 Mar; 228(3):201-7. PubMed ID: 20845257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective of pharmacologic vitreolysis.
    Gandorfer A
    Dev Ophthalmol; 2009; 44():1-6. PubMed ID: 19494646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocriplasmin for symptomatic vitreomacular adhesion.
    Blue Cross and Blue Shield Association
    Technol Eval Cent Assess Program Exec Summ; 2013 Aug; 28(5):1-3. PubMed ID: 24066370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.